
-
Immunovant NasdaqGS:IMVT Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Location: 320 West 37th Street, New York, NY, 10018, United States | Website: https://immunovant.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.082B
Cash
374.7M
Avg Qtr Burn
-81.23M
Short % of Float
33.30%
Insider Ownership
58.74%
Institutional Own.
56.33%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Batoclimab (IMVT-1401) Details Thyroid Eye Disease | Phase 3 Data readout | |
Batoclimab (IMVT-1401) Details Myasthenia gravis | Phase 3 Update | |
Batoclimab (IMVT-1401) Details Graves’ disease | Phase 3 Update | |
IMVT-1402 Details Rheumatoid arthritis | Phase 2b Data readout | |
IMVT-1402 Details Graves’ disease | Phase 2b Data readout | |
Batoclimab (IMVT-1401) Details Chronic inflammatory disorder | Phase 2b Update | |
IMVT-1402 Details Sjögren’s Disease (SjD) | Phase 2 Initiation | |
IMVT-1402 Details Autoimmune disease, Warm autoimmune hemolytic anemia | Phase 1 Update | |
Batoclimab (IMVT-1401) Details Warm autoimmune hemolytic anemia | Failed Discontinued |